Nuvalent(NUVL) Seeking Alpha·2025-01-10 18:22Investment Opportunities - Nuvalent's ALK-selective inhibitor, NVL-655, has been granted Breakthrough Therapy Designation (BTD) by the FDA, indicating its potential as a blockbuster therapy [2] - The company focuses on innovative therapies and pharmaceuticals with catalysts for potential acquisitions, particularly in the biotech and life-saving therapies sector [2] Analyst's Position - The analyst holds a beneficial long position in Nuvalent (NUVL) and several other pharmaceutical companies, including Pfizer (PFE), Eli Lilly (LLY), AstraZeneca (AZN), Takeda (TAK), Merck (MRK), Roche (RHHBY), Johnson & Johnson (JNJ), Amgen (AMGN), and Bristol-Myers Squibb (BMY) [3] Disclosure - The article is written by the analyst and reflects their personal opinions, with no compensation received other than from Seeking Alpha [3] - Seeking Alpha clarifies that its analysts are third-party authors, including both professional and individual investors, and the platform is not a licensed securities dealer, broker, or investment adviser [4]